Home  >  Products  >  JMY (junction mediating and regulatory protein, p53 cofactor ) Blocking Peptide (the N terminal of JMY)(100ug)
JMY (junction mediating and regulatory protein, p53 cofactor ) Blocking Peptide (the N terminal of JMY)(100ug)

JMY (junction mediating and regulatory protein, p53 cofactor ) Blocking Peptide (the N terminal of JMY)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-JMY Antibody (ARP64775_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP64775
Size: 100ug
Weight: 82kDa
Gene: 133746
Format: Lyophilized powder
Target: JMY acts both as a nuclear p53/TP53-cofactor and a cytoplasmic regulator of actin dynamics depending on conditions. In nucleus, JMY acts as a cofactor that increases p53/TP53 response via its interaction with p300/EP300. JMY increases p53/TP53-dependent transcription and apoptosis, suggesting an important role in p53/TP53 stress response such as DNA damage. In cytoplasm, JMY acts as a nucleation-promoting factor for both branched and unbranched actin filaments. JMY activates the Arp2/3 complex to induce branched actin filament networks. JMY also catalyzes actin polymerization in the absence of Arp2/3, creating unbranched filaments. JMY contributes to cell motility by controlling actin dynamics. JMY may promote the rapid formation of a branched actin network by first nucleating new mother filaments and then activating Arp2/3 to branch off these filaments. The p53/TP53-cofactor and actin activator activities are regulated via its subcellular location.
Alternative names: FLJ37870; MGC163496; WHDC1L3
See Full Product Listings >